Solifenacin Treatment for Neurogenic Detrusor Overactivity: Patient-Reported Outcomes (pros) from the Randomised Clinical Trial Sonic
De Ridder, Dirk Amarenco, G Finazzi, Agro E Angulo, J Kurenkov, A Wright, M Fagertun, H Compion, G #
Allen R. Liss
Annual Meeting of the International Continence Society edition:42 location:Beijing, China date:15-19 October 2012
Hypothesis / aims of study
Many patients with spinal cord injury (SCI) or multiple sclerosis (MS) develop neurogenic detrusor overactivity (NDO) (1,2). SONIC investigated the efficacy and safety of fixed doses of solifenacin as a treatment for NDO. Here we present preliminary results for patient-reported outcomes (PROs).